Chemotherapy Induced Peripheral Neuropathy (CIPN ) and it's Impact on Quality of Life in Patients Receiving Platinum and Taxanes at Assuit University Hospital
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 60
- 主要终点
- Rae of recovery in patients with CIPN who receiving taxanes and platinum
研究概览
简要总结
Neuropathies are a major cause of moderate to severe impairments in cancer patients.
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%.
详细描述
Neuropathies are a major cause of moderate to severe impairments in cancer patients .
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%.
There are six main substance groups that cause damage to neurons developing CIPN: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide).
Platinum-based chemotherapeutics (oxaliplatin, cisplatin and carboplatin) have the highest prevalence rates of CIPN, affecting ~ 70% of patients, often complicated by coasting Acute oxaliplatin-induced peripheral neuropathy (OIPN) can result in prolonged infusion times (~ 22%), dose reduction (15-43%) and treatment cessation (6-21.4%) Taxane-induced peripheral neuropathy (TIPN) (paclitaxel, Docitaxel and Cabazitaxel ) is the most common non-haematological adverse event of treatment,however, docetaxel is generally considered to be less neurotoxic than paclitaxel.
CIPN occurs in a dose-dependent manner usually ,duration of exposure, scheduling and combination therapies are also potential risk factors.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 and <75 .
- •Sex : Male or female
- •Adjuvant or metastatic
- •Receiving neurotoxic agents " platinum and taxanes "
- •No documentation of any other causes of neuropathy in their medical records as : congenital and DM
排除标准
- •Pt not receiving any neurotoxic CTH.
- •Detected other causes of neuropathy.
结局指标
主要结局
Rae of recovery in patients with CIPN who receiving taxanes and platinum
时间窗: Baseline
Possibility of recovery in patients with CIPN who receiving taxanes and platinum compounds in different chemotherapy regimens and assessment by nerve conduction test.
Number of patients with CIPN who receiving taxanes and platinum
时间窗: Baseline
Number of patients with CIPN who receiving taxanes and platinum compounds in different chemotherapy regimens
次要结局
未报告次要终点
研究者
Walaa Khalifa Fathy
Principal Investigator
Assiut University